Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanimilast Biomarker Study in COPD
NCT03004417Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tanimilast in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Started Oct 2016; status: completed.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03004417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004417.